Your browser doesn't support javascript.
loading
Risk stratification and treatment goals in pulmonary arterial hypertension.
Dardi, Fabio; Boucly, Athénaïs; Benza, Raymond; Frantz, Robert; Mercurio, Valentina; Olschewski, Horst; Rådegran, Göran; Rubin, Lewis J; Hoeper, Marius M.
Afiliación
  • Dardi F; Cardiology Unit, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy.
  • Boucly A; Université Paris-Saclay, Hôpital Bicêtre, Le Kremlin-Bicêtre, France.
  • Benza R; Icahn School of Medicine at Mount Sinai, New York, NY, USA.
  • Frantz R; Department of Cardiovascular Disease, Mayo Clinic, Rochester, MN, USA.
  • Mercurio V; Department of Translational Medical Sciences, Federico II University, Naples, Italy.
  • Olschewski H; Div. Pulmonology, Department Internal Medicine, Medical University of Graz, Graz, Austria.
  • Rådegran G; Department of Clinical Sciences Lund, Cardiology, Lund University and The Haemodynamic Lab, VO Heart and Lung Medicine, Skåne University Hospital, Lund, Sweden.
  • Rubin LJ; University of California San Diego School of Medicine, San Diego, CA, USA ljr@lewisrubinmd.com.
  • Hoeper MM; Department of Respiratory Medicine and Infectious Disease, Hannover Medical School and the German Center for Lung Research (DZL), Hannover, Germany.
Eur Respir J ; 2024 Aug 29.
Article en En | MEDLINE | ID: mdl-39209472
ABSTRACT
Risk stratification has gained an increasing role in predicting outcomes and guiding the treatment of patients with pulmonary arterial hypertension (PAH). The most predictive prognostic factors are three noninvasive parameters (World Health Organization functional class, 6-min walk distance and natriuretic peptides) that are included in all currently validated risk stratification tools. However, suffering from limitations mainly related to reduced specificity of PAH severity, these variables may not always be adequate in isolation for guiding individualised treatment decisions. Moreover, with effective combination treatment regimens and emerging PAH therapies, markers associated with pulmonary vascular remodelling are expected to become of increasing relevance in guiding the treatment of patients with PAH. While reaching a low mortality risk, assessed with a validated risk tool, remains an important treatment goal, preliminary data suggest that invasive haemodynamics and cardiac imaging may add incremental value in guiding treatment decisions.
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur Respir J Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Eur Respir J Año: 2024 Tipo del documento: Article País de afiliación: Italia Pais de publicación: Reino Unido